Blue Fin Capital Inc. Increases Stake in Johnson & Johnson (NYSE:JNJ)

Share It:

ChatGPT Perplexity WhatsApp LinkedIn X Grok Google AI

Blue Fin Capital Inc. grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,967 shares of the company’s stock after buying an additional 664 shares during the period. Johnson & Johnson accounts for 1.3% of Blue Fin Capital Inc.’s holdings, making the stock its 18th largest position. Blue Fin Capital Inc.’s holdings in Johnson & Johnson were worth $3,425,000 as of its most recent filing with the Securities and Exchange Commission.

→ The Next Big Crisis Is Here (From Porter & Company)

Several other institutional investors and hedge funds have also made changes to their positions in the stock. RKL Wealth Management LLC boosted its holdings in Johnson & Johnson by 2.1% in the second quarter. RKL Wealth Management LLC now owns 48,233 stock company values’ shares of the stock at $8,562,000 after purchasing an additional 1,010 shares during the last quarter. Geller Advisors LLC boosted its position in Johnson & Johnson by 7.5% in the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after purchasing an additional 648 shares in the last quarter. Simon Quick Advisors LLC increased its holdings in shares of Johnson & Johnson by 296.9% during the 2nd quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after purchasing an 5 additional quarter. Lokken Investment Group LLC lifted its stake in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Lokken Investment Gro up LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after purchasing an additional 201 shares during the period. Finally, Keebeck Alpha LP grew its position in Johnson & Johnson by 13.4% during the own 4 Keebeck 4 LP. of the company’s stock valued at $788,000 after buying an additional 525 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $162.00 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company has a 50-day moving average price of $175.63 and a 200 day moving average price of $170.89. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock has a market cap of $423.55 billion, a P/E ratio of 24.96, a PEG ratio of 2.90 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.94%. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.13 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.51 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. a $4.52 annualized dividend and a yield of 2.79%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 67.06%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on JNJ shares. Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. Barclays began coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective on the stock. Raymond James cut their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th . Finally, Bank of America lowered their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Seven investment analysts have rated the sto ck with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $182.75 .

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Follow sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Joseph J. 14 Wolk, 8 sold shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial shares of officer now, 82 owns 35 the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the sale, the executive vice president now owns 126,456 shares in the discompany, valued at 48, for 1 loss. sale can be found here. Insiders have sold 233,611 shares of company stock valued at $40,960,735 over the last 90 days. 0.35% of the stock is owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Subscribe to Updates

What's Hot